Previous 10 | Next 10 |
Deals and Financings Abbisko Therapeutics, a Shanghai novel drug biopharma, raised $70 million in a Series C financing led by Singapore's Temasek. The company has four clinical programs underway, and it intends to expand its discovery pipeline, which consists of small molecule targeted oncol...
AL008 is Alector’s dual function SIRP-alpha inhibitor and Fc gamma receptor activator antibody targeting the innate immune system for oncology indications The partnership with Innovent enables Alector to continue to expedite global development of it's immuno-oncology pipeline S...
Alector (NASDAQ: ALEC ): Q4 GAAP EPS of -$0.45 misses by $0.01 . More news on: Alector, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Continued execution across immuno-neurology platform, with multiple clinical, regulatory and operational milestones achieved in 2019 On track to initiate pivotal Phase 3 trial in patients with frontotemporal dementia with a progranulin mutation (FTD-GRN) in 2020 Strengthened b...
SOUTH SAN FRANCISCO, Calif., March 23, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC) today announced the addition of Paula Hammond, Ph.D., to the Company’s Board of Directors. Dr. Hammond is the David H. Koch Chair Professor of Engineering and Department Head, Chemical Engine...
ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Buy rating and $69 (55% upside) price target at Citigroup. More news on: ACADIA Pharmaceuticals Inc., Alector, Inc., GW Pharmaceuticals plc, Healthcare stocks news, , Stocks on the move, Read more ...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
The investment research arm of Barclays (NYSE: BCS ,LSE:BARC) is not worried about drug pricing concerns in the US; instead, it has a positive outlook for the country’s biopharma industry. On Wednesday (February 26), Barclays Capital launched its coverage of the US biopharma space w...
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Arnon Rosenthal, Ph.D., co-founder and chief executive officer of Alector, will present at the...
Alector (NASDAQ: ALEC ) initiated with Buy rating and $44 (52% upside) price target at Stifel. More news on: Alector, Inc., Aridis Pharmaceuticals, Inc., BioLife Solutions, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
--INVOKE-2 is the first global Phas e 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer’s disease (AD)-- --Baseline characteristics data for the INVOKE-2 study confirm a representative stud...
SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations related to the Company’s TREM2 and progranulin programs at the upcoming Alzheimer's Associatio...
SOUTH SAN FRANCISCO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in a corporate presentation at the H.C. Wainwright 5 th Annual Neuro Pers...